Analysis of risk factors and treatment outcome following methotrexate therapy in ectopic pregnancy

Authors

  • Paneerselvam Amudha Department of Obstetrics and Gynecology, Government Medical College, Pudukkottai, Tamil Nadu, India
  • Shenbagam G. Department of Obstetrics and Gynecology, Government Medical College, Pudukkottai, Tamil Nadu, India
  • Raji C. Department of Obstetrics and Gynecology, Government Medical College, Pudukkottai, Tamil Nadu, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20220370

Keywords:

Ectopic pregnancy, Risk factors, Methotrexate

Abstract

Background: Ectopic pregnancy is a significant cause of morbidity and mortality in first trimester of pregnancy. Awareness regarding risk factors for ectopic pregnancy aids in early diagnosis and timely medical intervention before tubal rupture occurs. This study was undertaken to analyze the risk factors for ectopic pregnancy and to study the treatment outcome following methotrexate therapy.

Methods: In this prospective study, 34 women with unruptured ectopic pregnancy selected for medical therapy were enrolled women with ectopic pregnancy who were hemodynamically stable with initial beta-human chorionic gonadotropin (β hCG) values of <5000 mIU/l, ectopic gestation mass size <5 cm and with no contraindication for methotrexate use were included in the study. Risk factors for ectopic pregnancy were studied and treatment outcome following single dose or 2 dose methotrexate regimen were analyzed.

Results: The mean age of the study group was 26.88±4.5 years. Highest incidence of ectopic pregnancy was noted in 26-30 years and in second gravidas. Successful treatment outcome was observed in 61.8% with single dose methotrexate (MTX) and in 23.5% with 2 doses. Overall success rate of MTX therapy was 85.3%. Surgical intervention was instituted in 14.7% when pretreatment β hCG levels were <1500 mIU/ml. Single dose MTX was successful in 91.7% and with 2 doses it was 100%. None developed any major side effects to methotrexate therapy.

Conclusions: MTX therapy is safe and effective in carefully selected women with ectopic pregnancy. Success rate of MTX therapy was 85.3%. MTX was most effective when pretreatment β hCG levels were less than 1500 mIU/ml.

Author Biographies

Paneerselvam Amudha, Department of Obstetrics and Gynecology, Government Medical College, Pudukkottai, Tamil Nadu, India

Associate Professor

Department of Obstetrics and Gynaecology

Shenbagam G., Department of Obstetrics and Gynecology, Government Medical College, Pudukkottai, Tamil Nadu, India

Senior Resident

Department of Obstetrics and Gynaecology

Raji C., Department of Obstetrics and Gynecology, Government Medical College, Pudukkottai, Tamil Nadu, India

Associate Professor

Department of Obstetrics and Gynaecology

References

Farquhar CM. Ectopic pregnancy. Lancet. 2005;366(9485):583-91.

Tahmina S, Daniel M, Solomon P. Clinical Analysis of Ectopic Pregnancies in a Tertiary Care Centre in Southern India: A Six-Year Retrospective Study. J Clin Diagn Res. 2016;10(10):13-6.

FOGSI GCPR on Ectopic pregnancy. Available at: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjRrfSOvNv1AhXr5nMBHdsrBj4QFnoECBMQAQ&url=https%3A%2F%2Fwww.fogsi.org%2Fwp-content%2Fuploads%2Fgcpr%2FEctopic-Pregnancy.pdf&usg=AOvVaw3oAyEpSCNJGdW39OizzSM1. Accessed on 27 September 2020.

Barnhart KT, Sammel MD, Gracia CR, Chittams J, Hummel AC, Shaunik A. Risk factors for ectopic pregnancy in women with symptomatic first-trimester pregnancies, Fertil Steril. 2006;86(1):36-43.

Committee on Practice bulletins- Gynecology. ACOG Practice bulletin No.191 summary: tubal ectopic pregnancy. Obstet Gynecol. 2018;131(2):409-11.

Ectopic pregnancy and miscarriage: diagnosis and initial management NICE guideline. 2019. Available at: www.nice.org.uk/guidance/ng126. Accessed on 27 September 2020.

Barnhart KT, Fay CA, Suescum M, Sammel MD, Appleby D, Shaunik A, Dean AJ. Clinical factors affecting the accuracy of ultrasonography in symptomatic first-trimester pregnancy. Obstet Gynecol. 2011;117(2):299-306.

Karaer A, Avsar FA, Batioglu S. Risk factors for ectopic pregnancy: a case-control study. Aust N Z J Obstet Gynaecol. 2006;46(6):521-7.

Atrash HK, Hughes JM, Hogue CJ. Ectopic pregnancy in the United States, 1970-1983. MMWR CDC Surveill Summ. 1986;35(2):29-37.

Coste J, Job-Spira N, Fernandez H, Papiernik E, Spira A. Risk factors for ectopic pregnancy: a case-control study in France, with special focus on infectious factors. Am J Epidemiol. 1991;133(9):839-49.

Westrom L, Bengtsson LP, Mardh PA. Incidence, trends and risks of ectopic pregnancy in a population of women. Br Med J (Clin Res Ed). 1981;282(6257):15-8.

Bouyer J, Coste J, Shojaei T, Pouly JL, Fernandez H, Gerbaud L, Job-Spira N. Risk factors for ectopic pregnancy: a comprehensive analysis based on a large case-control, population-based study in France. Am J Epidemiol. 2003;157(3):185-94.

Yeko TR, Handler A. The effect of aging on tubal function and ectopic pregnancy. Semin Reprod Endocrinol. 1991;9:215-20.

Doyle MB, DeCherney AH, Diamond MP. Epidemiology and etiology of ectopic pregnancy. Obstet Gynecol Clin North Am. 1991;18(1):1-17.

Ankum WM, Mol BW, Van der Veen F, Bossuyt PM. Risk factors for ectopic pregnancy: a meta-analysis. Fertil Steril. 1996;65(6):1093-9.

Job-Spira N, Coste J, Bouyer J, Tharaux-Deneux C, Fernandez H. Chromosomal abnormalities and ectopic pregnancy? New directions for aetiological research. Hum Reprod. 1996;11(2):239-42.

Fernandez H, Bouyer J, Coste J. The hidden side of ectopic pregnancy: the hormonal factor. Hum Reprod. 1996;11:243-4.

Marion LL, Meeks GR. Ectopic pregnancy: History, incidence, epidemiology, and risk factors. Clin Obstet Gynecol. 2012;55(2):376-86.

Perkins KM, Boulet SL, Kissin DM, Jamieson DJ; National ART Surveillance (NASS) Group. Risk of ectopic pregnancy associated with assisted reproductive technology in the United States, 2001-2011. Obstet Gynecol. 2015;125(1):70-8.

Decleer W, Osmanagaoglu K, Meganck G, Devroey P. Slightly lower incidence of ectopic pregnancies in frozen embryo transfer cycles versus fresh in vitro fertilization-embryo transfer cycles: a retrospective cohort study. Fertil Steril. 2014;101(1):162-5.

Li C, Zhao WH, Zhu Q, Cao SJ, Ping H, Xi X, et al. Risk factors for ectopic pregnancy: a multi-center case-control study. BMC Pregnancy Childbirth. 2015;15:187.

Sivalingam VN, Duncan WC, Kirk E, Shephard LA, Horne AW. Diagnosis and management of ectopic pregnancy. J Fam Plann Reprod Health Care. 2011;37(4):231-40.

Westrom L, Bengtsson LP, Mardh PA. The risk of Pelvic inflammatory disease in women using intrauterine contraceptive devices compared to nonusers. Lancet. 1976;2:221-4.

Vessey MP, Yeates D, Flave IR. Pelvic inflammatory disease and the intrauterine device: findings of large cohort study. Br Med J. 1981;282:855-7.

Tay JI, Moore J, Walker JJ. Ectopic pregnancy. BMJ. 2000;320(7239):916-9.

Egger M, Low N, Smith GD, Lindblom B, Herrmann B. Screening for chlamydial infections and the risk of ectopic pregnancy in a county in Sweden: ecological analysis. BMJ. 1998;316(7147):1776-80.

Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens. Obstet Gynecol. 2003;101(4):778-84.

Stovall TG, Ling FW. Single-dose methotrexate: an expanded clinical trial. Am J Obstet Gynecol. 1993;168(6):1759-62.

Gungorduk K, Asicioglu O, Yildirim G, Gungorduk OC. Comparison of single-dose and two-dose methotrexate protocols for the treatment of unruptured ectopic pregnancy. J Obstet and Gynaecol. 2011;31(4):330-4.

Practice Committee of American Society for Reproductive Medicine. Medical treatment of ectopic pregnancy: a committee opinion. Fertil Steril. 2013;100(3):638-44.

Pulatoglu C, Dogan O, Basbug A, Kaya Ae, Yildiz A, Temizkan O. Predictive factors of methotrexate treatment success in ectopic pregnancy: A single-center tertiary study. North Clin Istanb. 2018;5(3):227-31.

Mol F, Mol BW, Ankum WM, Veen FV, Hajenius PJ. Current evidence on surgery, systemic methotrexate and expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis. Human Reprod Update. 2008;14(4):309-19.

Bonin L, Pedreiro C, Moret S, Chene G, Gaucherand P, Lamblin G. Predictive factors for the methotrexate treatment outcome in ectopic pregnancy: A comparative study of 400 cases. Eur J Obstet Gynecol Reprod Biol. 2017;208:23-30.

Levin G, Saleh NA, Haj-Yahya R, Matan LS, Avi B. Predicting success of methotrexate treatment by pretreatment HCG level and 24-hour HCG increment. Int J Gynaecol Obstet. 2018;141(1):70-3.

Zhang J, Zhang Y, Gan L, Liu XY, Du SP. Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancy. BMC Pregnancy Childbirth. 2020;20(1):654.

Dhar H, Hamidi I, Rathi B. Methotrexate Treatment of Ectopic pregnancy: Experience at Nizwa Hospital Literature Review. Oman Med J. 2011;26(2):94-8.

Lipscomb GH, McCord ML, Stovall TG, Huff G, Portera SG, Ling FW. Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies. N Engl J Med. 1999;341(26):1974-8.

Alleyassin A, Khademi A, Aghahosseini M, Safdarian L, Badenoosh B, Hamed EA. Comparison of success rates in the medical management of ectopic pregnancy with single-dose and multiple-dose administration of methotrexate: a prospective, randomized clinical trial. Fertil Steril. 2006;85(6):1661-6.

Downloads

Published

2022-02-25

Issue

Section

Original Research Articles